Oxford Nanopore Technologies plc

BATS-CHIXE:ONTL Stock Report

Market Cap: UK£1.4b

Oxford Nanopore Technologies Valuation

Is ONTL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ONTL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ONTL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ONTL's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ONTL?

Key metric: As ONTL is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ONTL. This is calculated by dividing ONTL's market cap by their current revenue.
What is ONTL's PS Ratio?
PS Ratio8.1x
SalesUK£167.75m
Market CapUK£1.36b

Price to Sales Ratio vs Peers

How does ONTL's PS Ratio compare to its peers?

The above table shows the PS ratio for ONTL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.7x
ERGO Ergomed
4.6x8.8%UK£701.1m
MXCT MaxCyte
8.2x20.5%UK£293.2m
HVO hVIVO
2.2x4.4%UK£144.6m
DXRX Diaceutics
3.8x1.8%UK£98.0m
ONTL Oxford Nanopore Technologies
8.1x22.6%UK£1.4b

Price-To-Sales vs Peers: ONTL is expensive based on its Price-To-Sales Ratio (8.1x) compared to the peer average (4.7x).

Price to Sales Ratio vs Industry

How does ONTL's PS Ratio compare vs other companies in the European Life Sciences Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
No. of Companies8PS03.26.49.612.816+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: ONTL is expensive based on its Price-To-Sales Ratio (8.1x) compared to the European Life Sciences industry average (4.4x).

Price to Sales Ratio vs Fair Ratio

What is ONTL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ONTL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio8.1x
Fair PS Ratio5.3x

Price-To-Sales vs Fair Ratio: ONTL is expensive based on its Price-To-Sales Ratio (8.1x) compared to the estimated Fair Price-To-Sales Ratio (5.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ONTL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUK£1.42
UK£1.86
+30.6%
28.4%UK£2.82UK£1.00n/a10
Nov ’25UK£1.35
UK£1.85
+36.4%
28.8%UK£2.82UK£1.00n/a10
Oct ’25UK£1.60
UK£1.85
+15.4%
28.8%UK£2.82UK£1.00n/a10
Sep ’25UK£1.18
UK£1.89
+59.3%
28.0%UK£2.82UK£1.00n/a10
Aug ’25UK£1.30
UK£1.78
+37.5%
25.0%UK£2.50UK£1.00n/a9
Jul ’25UK£0.98
UK£1.97
+100.9%
34.4%UK£3.50UK£1.00n/a10
Jun ’25UK£1.07
UK£1.98
+85.7%
33.8%UK£3.50UK£1.00n/a10
May ’25UK£1.01
UK£2.02
+100.2%
33.4%UK£3.50UK£1.00n/a10
Apr ’25UK£1.22
UK£2.20
+80.0%
30.3%UK£3.50UK£1.15n/a10
Mar ’25UK£1.33
UK£2.65
+100.1%
31.1%UK£4.00UK£1.30n/a10
Feb ’25UK£1.56
UK£2.81
+80.3%
25.6%UK£4.00UK£1.55n/a10
Jan ’25UK£2.10
UK£3.11
+48.1%
30.3%UK£5.29UK£1.90n/a10
Dec ’24UK£1.93
UK£3.14
+62.8%
30.9%UK£5.29UK£1.90n/a10
Nov ’24UK£2.00
UK£3.28
+64.3%
29.2%UK£5.29UK£1.90UK£1.3510
Oct ’24UK£2.06
UK£3.37
+64.1%
28.3%UK£5.29UK£1.90UK£1.6010
Sep ’24UK£2.37
UK£3.42
+44.7%
26.9%UK£5.29UK£1.90UK£1.1810
Aug ’24UK£2.60
UK£3.43
+32.1%
26.7%UK£5.29UK£1.90UK£1.3010
Jul ’24UK£2.14
UK£3.43
+60.5%
26.7%UK£5.29UK£1.90UK£0.9810
Jun ’24UK£2.67
UK£3.47
+30.0%
28.0%UK£5.29UK£1.70UK£1.0710
May ’24UK£2.29
UK£3.47
+51.2%
28.0%UK£5.29UK£1.70UK£1.0110
Apr ’24UK£2.23
UK£3.52
+57.8%
28.0%UK£5.29UK£1.70UK£1.2210
Mar ’24UK£2.10
UK£4.30
+104.7%
24.8%UK£6.50UK£2.70UK£1.339
Feb ’24UK£2.39
UK£4.70
+96.7%
25.1%UK£6.71UK£3.10UK£1.568
Jan ’24UK£2.48
UK£5.30
+113.8%
25.0%UK£7.20UK£4.00UK£2.107
Dec ’23UK£2.62
UK£5.37
+105.5%
24.0%UK£7.20UK£4.00UK£1.937
Nov ’23UK£2.82
UK£5.36
+90.4%
22.5%UK£7.20UK£4.00UK£2.008

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Formycon

€844.9m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€48.65

7D

3.6%

1Y

-24.5%

hVIVO

UK£134.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.21

7D

-3.8%

1Y

4.9%

Regeneron Pharmaceuticals

US$81.0b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$754.96

7D

2.0%

1Y

-7.1%